롱에버론(LGVN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.74 (+6.06%), 시가총액 $0.02B, 52주 범위 $0.48 ~ $1.74.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
롱에버론의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
롱에버론의 현재 주가는 $0.74 (+6.06%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
롱에버론의 시가총액은 약 $0.02B입니다.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOM